China:  CAR-T

China: CAR-T

In April of 2016, Immune Therapeutics, Inc. entered into a binding letter of intent with Super T-Cell Cancer Company, a newly formed Chinese corporation, for the acquisition of Chinese Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy, Immuno-Oncology patents (pending), manufacturing technology, and clinical data.

  • 1
  • 2